Altimmune initiated with a Buy at UBS
The Fly

Altimmune initiated with a Buy at UBS

UBS analyst Eliana Merle initiated coverage of Altimmune (ALT) with a Buy rating and $26 price target The firm sees Altimmune as “highly differentiated” in the metabolic space, with near-term upside from likely positive metabolic dysfunction-associated steatohepatitis data in Q2 of 2025. The firm has “high conviction” in pemvidutide’s success in the Phase 2b trial and assigns a 50% probability of success. It believes Altimmune’s long-term opportunities are underappreciated.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App